
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BBV154
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Bharat Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
AIIMS Delhi to Conduct Phase 2 of Bharat Biotech's Nasal Vaccine Trials
Details : Bharat Biotech's intranasal vaccine, BBV154, received regulatory approval for second phase trials in August. The trials will begin in a couple of weeks after permission is granted by the committee.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 09, 2021
Lead Product(s) : BBV154
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Bharat Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Alchem International Private Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : After ten days of treatment with Phytorelief along with standard management, 83% of Covid-19 patients, with mild or moderate symptoms, turned negative in a trial conduct in AIIMS Patna.
Product Name : Phytorelief-CC
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Alchem International Private Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BGR-34,Glibenclamide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
AIIMS Researchers Find Ayurvedic-Allopathic Combo BGR-34 & Glibenclamide in Controlling Diabetes
Details : In the Animal experimental study, doctors have found that the pace of diabetes growth can be halted if allopathic drug is integrated with BGR-34, a herbal formulation enriched with antioxidant properties which stops bad cholesterol from accumulating in t...
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 03, 2021
Lead Product(s) : BGR-34,Glibenclamide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AIIMS Find Ivermectin Prophylaxis Reduces Infection in Covid-19 Patients
Details : A study by All India Institutes of Medical Sciences (AIIMS)-Bhubaneswar in the Indian state of Odisha found that two doses of potential drug ivermectin prophylaxis resulted in a 73% reduction in Covid-19 infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
